Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine

DB16431ExperimentalVaccines

Receptor binding domain SARS-CoV-2 Hepatitis B surface antigen virus-like particle vaccine (RBD SARS-CoV-2 HBsAg VLP vaccine), is a virus-like particle vaccine candidate where the RBD antigen is conjugated to the... Virus-like particles (VLPs) are protein-based vaccines that stimulate high immune responses because of the VLPs’ repetitive structures.

Also known as: RBD SARS-CoV-2 HBsAg VLP vaccine
Code names: Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine

What you can answer from here — as of March 06, 2025

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account